



Characterization of Tigogenin Isolated from Solanum Nigrum and its Hepatoprotective Property

¹Awadhesh Kumar, ²Padmakshi Singh

¹Department of Chemistry, T.D.P.G.College, Jaunpur (U.P.)

²Department of Chemistry, T.D.P.G.College, Jaunpur (U.P.)

Article History:

Received : 2026-03-03

Revised : 2026-04-14

Accepted : 2026-04-21

Published : 2026-04-28

Abstract

This study evaluates the isolation, structural characterization, and hepatoprotective efficacy of the steroidal sapogenin, Tigogenin (SN-1), obtained from *Solanum nigrum*. Column chromatography of the plant extract yielded a crystalline solid (SN-1) with a melting point of 203–204°C and an R_f value of 0.45–0.52 (Chloroform:Methanol, 9:1). The identity and high purity of Tigogenin (C₂₇H₄₄O₃) were confirmed using elemental analysis, IR spectroscopy (O–H stretching at 3524cm⁻¹), ¹H-NMR (δ 0.70–1.20 ppm for methyl protons and δ 3.30–3.60 ppm for –CHOH), and Mass Spectrometry [M]⁺ at m/z 416). Acetylation of the parent compound successfully yielded Tigogenin Acetate (M.P. 204–208°C), verified via spectral studies.

The hepatoprotective potential of the *S. nigrum* alcoholic extract (100–400 mg/kg) and isolated Tigogenin (10–20 mg/kg) was evaluated against carbon tetrachloride (CCl₄) -induced hepatotoxicity in Wistar albino rats over 14 days. Administration of CCl₄ alone caused severe hepatic impairment, significantly elevating serum transaminases (ALT, AST, ALP, GGT) and bilirubin, while depleting albumin levels. Co-treatment with *S. nigrum* extract and Tigogenin demonstrated potent, dose-dependent hepatoprotection. Notably, the extract at 400 mg/kg and Tigogenin at 20 mg/kg exhibited maximum therapeutic efficacy, effectively restoring liver enzymes, bilirubin, and protein synthesis (albumin) toward near-normal baseline levels. These findings conclude that *S. nigrum* and its active constituent, Tigogenin, act as powerful natural antioxidant and hepatoprotective agents.

Keywords: *S. nigrum*, Tigogenin, Steroidal sapogenin, Hepatoprotective.

1. Introduction

The global demand for herbal medicines is increasing due to the adverse effects associated with many allopathic drugs¹. International organizations such as the World Health Organization have emphasized the need for quality control and standardization of Ayurvedic products using modern scientific methods². Nature provides a wide

range of medicinal resources in the form of herbs, plants, and algae that help treat many diseases with minimal toxicity². Herbal medicines are gaining popularity because of their effectiveness, affordability, and fewer side effects. *Solanum nigrum* is a highly adaptable plant species commonly found in disturbed habitats³. It grows along roadsides, railway tracks, riverbanks, and quaysides. The plant contains steroidal saponins, which include compounds like diosgenin, solasodine, solasonine, and solamargine, known for their anticancer, anti-inflammatory, and immunomodulatory properties⁴. It also contains alkaloids, primarily nitrogen-containing compounds, contributing to its pharmacological activities⁵. Flavonoids and polyphenols, such as quercetin and kaempferol derivatives, provide antioxidant and hepatoprotective effects⁶. Additionally, *S. nigrum* contains terpenoids, organic acids (like caffeic acid and chlorogenic acid), and carotenoids (β -carotene, xanthophyll), which enhance its protective role against oxidative stress⁶. Glycosides and other sugar-bound derivatives further augment its bioactivity. The rich and complex phytochemical profile of *S. nigrum* underlies its widespread use in traditional medicine systems like Ayurveda, offering therapeutic benefits for liver disorders, inflammation, cancer, and immune support⁷.

Solanum nigrum L. (Black Nightshade) is a well-known medicinal plant traditionally used for the treatment of liver disorders. Numerous pharmacological studies have demonstrated its significant hepatoprotective activity against chemically induced liver damage. The hepatoprotective effect of *S. nigrum* is mainly attributed to its rich content of steroidal alkaloids, glycoproteins, flavonoids, saponins, and phenolic compounds, which possess strong antioxidant and anti-inflammatory properties⁸. Experimental studies have shown that aqueous and ethanolic extracts of *S. nigrum* effectively reduce elevated serum liver enzymes such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and bilirubin levels in hepatotoxic animal models^{9,10}. The plant also enhances endogenous antioxidant defenses by increasing glutathione (GSH), superoxide dismutase (SOD), and catalase activities while reducing lipid peroxidation and oxidative stress^{11,12}. Histopathological investigations have revealed that treatment with *S. nigrum* promotes regeneration of damaged hepatocytes and restores normal liver architecture¹³. Additionally, studies suggest that the plant inhibits inflammatory mediators and fibrotic processes associated with chronic liver injury¹⁴. Due to these protective mechanisms, *S. nigrum* is considered a promising natural hepatoprotective agent and may serve as a potential source for the development of liver-protective herbal formulations¹⁵.

Material and Method:

Collection of Medicinal Plant

The medicinal plant species *Solanum nigrum* was chosen, whole plant including stem, leaf, fruit and root were collected from agricultural fields of Jaunpur district U.P. during May 2023, and plant identified by experts from botanical department Banaras Hindu University, Varanasi, and further compared with herbarium specimen of *S. nigrum*. All collected plants were washed thoroughly and dried in shade until complete dehydration. Plant parts separated (stem, leaf and fruits, root) were cleaned and dried under shade. The dried plant materials were then ground properly into fine powder. The plant materials were transferred to the laboratory for phytochemical and biological investigation and experimental analytical study.

Preparation of extracts

The powdered plant material of nigrum was used for the preparation of different solvent extracts. A measured quantity of dried powder was subjected to successive extraction using petroleum ether, chloroform and alcohol in increasing order of polarity. Each extraction was carried out separately using a Soxhlet apparatus for 72 hours until complete exhaustion of the plant material. After extraction, the obtained solutions were filtered and concentrated under reduced pressure using a rotary evaporator. The dried extracts were collected, weighed and stored in airtight containers at low temperature. These extracts were further used for phytochemical screening and biological activity studies.

Extraction

The extraction of bioactive compounds from *Solanum nigrum* typically begins with cleaning and drying the plant parts, which are then ground to a fine powder. This powdered material is subjected to solvent extraction to separate chemical constituents based on polarity. Soxhlet apparatus employed for extraction with solvents of increasing polarity like petroleum ether, chloroform, and methanol/ethanol to remove lipids and extract alkaloids, glycosides, phenolics, and flavonoids^{16,17}.

Chemical and Reagents

Immobilized lipase (triacylglycerol hydrolase, EC 3.1.1.3; Novozym® 435, 10000 PLU/g) from *Candida Antarctica*, supported on a macroporous acrylic resin with a water content of 3 % (w/w) was purchased from Novo Nordisk A/S (Bagsvaerd, Denmark). Chloroform, n-hexane was obtained from Fisher chemicals. Betulinic acid was purified from Malaysian *Callistemon speciosus* by previous method. Acetic anhydride was purchased from Acros Organics, Belgium. Ethyl acetate, celite® 545, Na₂SO₄, K₂CO₃ and HCl were purchased from Merck, Germany. All chemicals were of analytical reagent grade. Silica gel G & H and other chemicals were purchased from local suppliers Jaunpur and were used further without any adulteration.

Instrumentation

Melting points were recorded on standard melting point apparatus and were in corrected. UV spectra were recorded on UV-cary-100 spectrophotometer in ISSC. Infra Red Spectra (FT-IR) were recorded on Shimadzu FT-IR-8300 spectro photometer in KBR. disc and value are expressed in cm⁻¹. ¹H NMR spectra were recorded on a Bruker AC 40w MHz spectrometer using TMS as internal standard in DMSO-d₆. Elemental analysis (N, S) was carried out with Euroea-Eiermental analyzer Italia.

Result and Discussion:

Eluents isolated from column 31 to 42 were pooled together and crystallized. Further purification may be carried out using preparative TLC or recrystallization. The isolated SN-1 is then characterized by melting point, TLC R_f, IR spectroscopy, and ¹H NMR analysis to confirm purity and identity of tegogenin.

Physical Data of SN-1:

The compound was obtained as a crystalline solid and exhibited a melting point in the range of 203–204°C (200°C -202°C)^{18,19}, which closely matches reported literature values for tigogenin, indicating high purity. Thin-layer chromatographic analysis using chloroform: methanol (9:1) as the mobile phase showed a single well-defined spot with an R_f value between 0.45 and 0.52, comparable to that of the reference standard. Visualization after spraying with anisaldehyde–sulfuric acid reagent produced a characteristic colored spot, further supporting its identity. Elemental

analysis of the isolated compound corresponded well with the theoretical composition of tigogenin (molecular formula $C_{27}H_{44}O_3$). The calculated carbon and hydrogen contents were 74.95% and 10.25%, respectively, while the experimentally found values ranged from 74.60–74.90% for carbon and 10.10–10.30% for hydrogen.




Fig. 1: IR spectra of SN-1

IR spectral analysis of isolated tigogenin showed characteristic absorption bands comparable to the standard. A sharp free O–H stretching band appeared around 3524 cm^{-1} with a broad hydrogen-bonded O–H band. Aliphatic C–H stretching, C–H bending, and C–O stretching vibrations confirmed the steroidal sapogenin structure.

^1H NMR spectra of SN-1:

The ^1H -NMR spectrum of SN-1 exhibits characteristic signals confirming its steroidal sapogenin structure. Methyl protons appear as singlets and doublets in the region δ 0.70–1.20 ppm, corresponding to angular CH_3 groups of the steroid nucleus. Multiplet signals observed between δ 1.20–2.20 ppm are assigned to methylene and methine protons of the saturated rings. A downfield signal around δ 3.30–3.60 ppm corresponds to the proton attached to the hydroxyl-bearing carbon (–CHOH), confirming the presence of a free hydroxyl group. The overall proton distribution and chemical shifts are consistent with reported ^1H -NMR data of Tigogenin isolated from *Solanum* species, supporting its identity and purity².

Mass Spectra of SN-1:

Table-1: Mass spectra of SN-1

m/z value	Assignment
416	Molecular ion peak $[\text{M}]^+$ ($C_{27}H_{44}O_3$)
398	$[\text{M} - \text{H}_2\text{O}]^+$ (loss of hydroxyl group)
345	Fragment due to side-chain cleavage
301	Steroidal ring fragmentation
255	Cleavage within rings A/B
189	Further breakdown of steroid nucleus
147	Low-mass characteristic fragment
109	Secondary fragmentation ion
69	Alkyl fragment ion
43	Typical hydrocarbon fragment

On the basis of above spectral study we conclude following structure of tigogenin as SN-1.




Fig. 2: Structure of Tigogenin

Tigogenin is a steroidal sapogenin with a core structure of a fused cyclopentanoperhydrophenanthrene ring system (the steroid backbone), specifically a (25R)-5 α -spirostan-3 β -ol, featuring a spiro-fused pyran ring and a hydroxyl group at C-3, making it a key precursor for synthesizing steroid hormones. Its formula is C₂₇H₄₄O₃.

Acetylation of Tigogenin: Tigogenin acetate can be synthesized directly from the parent compound, tigogenin. Tigogenin is reacted with acetic anhydride in pyridine, often with heating (e.g., on a steam bath) for approximately 0.5 to 1 hour. M.P. of Tigogenin acetate is 204–208 °C₂₀.

Table-2: Characterization of SN-1 Derivatives

IR cm ⁻¹	¹ H NMR δ (ppm)
1721–1735	~3.5–4.5, m, 1H (Typical spirostan pattern)
Ester Carbonyl, 1240–1250	~1.5–2.5, m, 1H (Ring A methylene adjacent)
Acetate C-O, 984, 920, 902, 860	~1.0–2.0, m, 2–4H (Alkyl protons)
Spirostan Ring, 2835–2974	~0.8–2.5, m, multiple (Ring protons and methylenes)
Aliphatic CH	~0.9–1.1, d, 3H (Secondary methyl)
	~0.8–1.0, s, 3H (Tertiary methyl)
	~0.7–0.9, s, 3H (Tertiary methyl)
	~2.02–2.15, s, 3H (Characteristic acetate singlet)

On the basis of above spectral study the proposed derivative is Tigogenin Acetate.




Fig.3: Structure of Tigogenin Acetate

Hepatoprotective properties of *S.nigrum* & tegogenin:

S. nigrum has been shown to possess significant hepatoprotective activity through multiple experimental models, particularly against chemical-induced liver injury. The aqueous leaf extract of *S. nigrum* significantly reversed carbon tetrachloride (CCl₄)-induced hepatotoxicity in albino rats by lowering elevated liver enzymes (ALT, AST) and restoring antioxidant markers such as glutathione (GSH), superoxide dismutase

(SOD), and catalase (CAT) to near-normal levels. Active compound tegogenin demonstrated potent mitigation of CCl₄-induced oxidative stress and liver injury in rats, with decreases in serum transaminases and improvements in tissue antioxidant status²¹. Supplementation of *S. nigrum* also showed protective effects against fatty liver and lipid peroxidation in high-fat diet models, indicating its role in reducing oxidative stress and maintaining hepatic function²². Additionally, earlier studies have reported that *S. nigrum* extracts reduce the severity of histopathological lesions and biochemical markers in chemically induced liver damage, further supporting its protective efficacy. Alcoholic extract of plant and tegogenin act as a natural hepatoprotective agent, likely due to its rich antioxidant phytochemicals²³.

Experimental Design:

40 male Wistar albino rats were randomly divided into eight groups (I-VIII) of five animals in each group.

Table 3 - Experimental protocol

Group	Treatment
Group 1	Distilled water only for 14 days
Group 2	2.0 ml/kg bw CCl ₄ alone for a single administration
Group 3	2.0 ml/kg bw CCl ₄ + 100 mg/kg <i>S.nigrum</i> alcoholic extract for 14 days
Group 4	2.0 ml/kg bw CCl ₄ + 200 mg/kg <i>S.nigrum</i> alcoholic extract for 14 days
Group 5	2.0 ml/kg bw CCl ₄ + 300 mg/kg <i>S.nigrum</i> alcoholic extract for 14 days
Group 6	2.0 ml/kg bw CCl ₄ + 400 mg/kg <i>S.nigrum</i> alcoholic extract for 14 days
Group 7	2.0 ml/kg bw CCl ₄ + 10 mg/kg tegogenin solution for 14 days
Group 8	2.0 ml/kg bw CCl ₄ + 20 mg/kg tegogenin solution for 14 days

For hepatoprotective enzyme such as Alkaline phosphatase (ALP), Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Gamma glutamyl transferase (GGT), Albumin, BIL Bilirubin(ALB) examined in serum of albino rat given in table.

Table-4: Effect of *S.nigrum* extract and solasodine on liver enzyme.

Group	ALP (mg/dl)	ALT (U/L)	AST (U/L)	GGT (mg/dl)	ALB (mg/dl)	BIL (mg/dl)
1	60.13±1.64	92.92±2.26	69.47±1.37	7.65±0.21	54.43±2.18	30.02±1.77
2	97.1 ± 1.79	138.8±3.64	108.79±3.26	10.7±0.45	26.24±0.88	55.27±1.91
3	62.4 ± 2.16	95.61±2.23	72.5 ± 1.47	7.9 ± 0.4	50.12±1.57	32.57 ± 1.3
4	82.76±3.38	120.07±3.18	90.21 ± 2.41	10.39±0.55	30.4 ± 0.92	45.89±2.19
5	71.27±2.54	100.94 ± 2.3	84.46 ± 2.17	8.84 ± 0.67	38.93±1.27	39.43±1.44
6	64.99±1.39	93.83 ± 2.16	75.57 ± 1.64	8.22 ± 0.59	49.65±1.52	33.38±1.35
7	81.85±3.29	121.24±3.10	91.72 ± 2.9	9.41 ± 0.56	28.14±0.81	35.12±2.36
8	68.36±1.23	94.41 ± 2.29	78.21 ± 1.71	7.85 ± 0.69	52.12±1.61	32.2 ± 1.37




Fig 4: Effect of S.nigrum extract and solasodine on ALP, ALT & AST




Fig 5: Effect of S.nigrum extract and tigogenin on ALP, ALT & AST

The table summarizes liver biochemical markers (ALP, ALT, AST, GGT), a synthetic-function marker (albumin), and an excretory marker (bilirubin) across eight concentrations, reported as mean \pm SD. Overall, Group 2 shows the most pronounced biochemical disturbance, with the highest ALP (97.1), ALT (138.8), AST (108.79), GGT (10.7) and bilirubin (55.27), alongside the lowest albumin (26.24), suggesting maximal hepatic injury with impaired synthetic capacity²⁴.

Group 1 represents the best biochemical profile in this dataset, with comparatively lower enzyme activities (ALP 60.13; ALT 92.92; AST 69.47; GGT 7.65) and bilirubin (30.02), and the highest albumin (54.43), consistent with minimal hepatocellular damage and preserved protein synthesis. Relative to Group 2, all other concentrations (3–8) show partial normalization: transaminases and cholestatic enzymes decline and albumin rises, indicating varying degrees of hepatoprotection or recovery^{25,26}.

Among the “improved” groups, Group 3 and 6 appear closest to the healthier pattern because ALT/AST are relatively lower (95.61/72.5 and 93.83/75.57, respectively)

while albumin is relatively higher (50.12 and 49.65) and bilirubin remains near the lower end of the dataset (32.57 and 33.38). Group 4 and 5 show intermediate injury, with higher bilirubin (45.89 and 39.43) and moderate enzyme elevations, implying incomplete restoration of hepatocyte integrity and bile handling. Interestingly, Group 7 shows a moderate enzyme profile but relatively low albumin (29.34), which may indicate that synthetic function lags behind enzymatic recovery or reflects nutritional/protein status effects that can influence albumin independent of acute enzyme release^{27,28}.

Discussion:

In experimental hepatotoxicity models, hepatoprotection is inferred when treatment prevents the toxin-induced rise in serum ALT and AST (hepatocellular leakage enzymes) and reduces ALP/GGT (cholestatic/biliary enzymes), while normalizing bilirubin and restoring albumin/synthetic function²⁹⁻³¹. Recent evidence supports *Solanum nigrum* (*S. nigrum*) extract as a hepatoprotective intervention^{32,33}: Study on methanolic leaf extract reported that CCl₄ increased ALT and AST, while *S. nigrum* treatment significantly reduced these activities and improved liver histology, consistent with membrane stabilization and antioxidant defense³⁴. Similarly, experimental study with aqueous *S. nigrum* extract found that CCl₄ elevated ALT, ALP and total bilirubin, whereas *S. nigrum* significantly limited the rise of these markers and improved histopathology³⁵.

For solasodine (a steroidal alkaloid from *Solanum* spp.), in vivo work indicates hepatoprotective potential against CCl₄ toxicity, reporting restoration of hepatocyte architecture and protective effects when solasodine was administered (including in combination regimens), which aligns with lowering of injury-related enzyme leakage and oxidative stress in hepatoprotection studies³³. When interpreting solasodine treatment, dose and safety remain important because some datasets flag hepatotoxicity risk signals in predictive toxicity assessments, so enzyme monitoring (ALT/AST, bilirubin) is essential during efficacy evaluation. Overall, *S. nigrum* extract (and potentially solasodine under controlled dosing) can be discussed as hepatoprotective by improving serum enzyme patterns and functional indices alongside histological recovery³⁶.

Reference

1. Atanu, F. O., Ebiloma, U. G., & Ajayi, E. I. (2011). A review of the pharmacological aspects of *Solanum nigrum* Linn. *Biotechnology and Molecular Biology Reviews*, 6(1), 1–8.
2. Mani, R. K., Paramashree, J. B., Bharathi, D. R., & Ahmed, S. S. (2021). The traditional and pharmacological properties of *Solanum nigrum*: A review. *International Journal of Indigenous Herbs and Drugs*, 6(2), 1–10.
3. Saleem, T. M., Chetty, C. M., Ramkanth, S., Rajan, V. S. T., Kumar, K. M., & Gauthaman, K. (2009). *Solanum nigrum* Linn.—A review. *Pharmacognosy Reviews*, 3(6), 342–345.
4. Khan, M. A., Ahmad, W., & Singh, R. (2021). Phytochemical profiling and neuropharmacological potential of *Solanum nigrum*. *Pharmacognosy Reviews*, 15(30), 96–104.
5. Kumar, S., Sharma, A., & Verma, R. (2021). Molecular mechanisms underlying anticancer activity of medicinal plants. *Biomedicine & Pharmacotherapy*, 139, 111620.

6. Das, A., Kumar, V., & Singh, D. (2021). Phytochemical profiles and antimicrobial efficacy of *Solanum nigrum* extracts. *Pharmacognosy Journal*, 13(2), 457–464.
7. Verma, S., Tripathi, Y. B., & Dubey, G. P. (2022). Role of plant-based bioactive compounds in modulation of GABAergic neurotransmission. *Frontiers in Pharmacology*, 13, 874562.
8. Patel, N., Mehta, A., & Joshi, D. (2023). Antioxidant and neuroprotective effects of *Solanum nigrum* against seizure-induced oxidative stress. *Journal of Herbal Medicine*, 38, 100635.
9. Park, S. Y., Kim, J. H., & Lee, M. Y. (2023). Immunomodulatory and anticancer effects of traditional medicinal plants. *Phytomedicine*, 108, 154521.
10. Wang, H., Li, Y., & Zhang, J. (2019). Anticancer potential of *Solanum nigrum* extracts against human cancer cell lines. *Journal of Ethnopharmacology*, 236, 94–102.
11. Hameed, I. H., Cotos, M. R. C., & Hadi, M. Y. (2017). A review: *Solanum nigrum* L. antimicrobial, antioxidant properties, hepatoprotective effects and analysis of bioactive natural compounds. *Research Journal of Pharmacy and Technology*, 10(11), 4063–4068.
12. Sharma, V., Gupta, R., & Singh, B. (2019). Protective effects of *Solanum nigrum* against chemically induced cellular injury. *Journal of Ethnopharmacology*, 244, 112138.
13. Hsieh, C. C., Fang, H. L., Lina, W. C., & Chung, J. G. (2008). Inhibitory effect of *Solanum nigrum* on thioacetamide-induced liver fibrosis in mice. *Journal of Ethnopharmacology*, 119(1), 117–121.
14. Li, J., Li, Q., Feng, T., & Li, K. (2014). Antioxidant and hepatoprotective activities of *Solanum nigrum* extracts against chemically induced liver injury. *Journal of Medicinal Plants Research*, 8(12), 497–503.
15. Li, Y., Zhang, Y., Wang, X., & Chen, H. (2025). Progress in *Solanum nigrum* L. research: Traditional uses, phytochemistry, pharmacological activities, quality control, and clinical applications. *Journal of Ethnopharmacology*, 343, 119632.
16. Chen, Y. L., Lin, C. F., & Hsu, C. Y. (2022). In vivo antitumor efficacy of *Solanum nigrum* in experimental models. *Journal of Herbal Medicine*, 32, 100541.
17. Nabaa M.Ibrahem and Zainab J. Awad (2013) Phytochemical Study of Steroidal Sapogenin “Tigogenin” Present in the Leaves of *Yucca aloifolia* Cultivated in Iraq, *Iraqi J Pharm Sci*, Vol.22(2), 1-8.
18. Chase, C.R., Jm, Pratt, R. (1949). Fluorescence of powdered vegetable drugs with particular reference to development of a system of identification. *J. Am. Pharm Assoc.*, 38: 324-31.
19. Nabaa M.Ibrahem, and Zainab J. Awad (2013) Phytochemical Study of Steroidal Sapogenin “Tigogenin” Present in the Leaves of *Yucca aloifolia* Cultivated in Iraq, *Iraqi J Pharm Sci*, Vol.22(2), 1-8.
20. Reddy, N. S., & Reddy, M. S. (2022). Evaluation of methanolic and ethanolic *Solanum nigrum* extracts against bacterial and fungal pathogens. *Journal of Ethnopharmacology*, 285, 114866.
21. Heo, K. S., & Lim, K. T. (2020). Antitumor activity of glycoprotein isolated from *Solanum nigrum*. *International Journal of Biological Macromolecules*, 150, 934–942.
22. Chen, X., Dai, X., Liu, Y., Zhang, M., & Wang, Z. (2022). *Solanum nigrum* Linn.: An insight into current research on traditional uses, phytochemistry, and

- pharmacology. *Frontiers in Pharmacology*, 13, 918071. <https://doi.org/10.3389/fphar.2022.918071>
23. Liu, F. P., Ma, X., Li, M. M., Liu, Y. Z., & Chen, Y. G. (2016). Hepatoprotective effects of *Solanum nigrum* against ethanol-induced injury in primary hepatocytes and mice. *Journal of the Chinese Medical Association*, 79(2), 65–71.
 24. Wang, H. C., Chung, P. J., Wu, C. H., Lan, K. P., Yang, M. Y., & Wang, C. J. (2011). *Solanum nigrum* Linn. water extract inhibits metastasis in hepatocellular carcinoma cells. *Journal of Agricultural and Food Chemistry*, 59(11), 5801–5808.
 25. Rajathi, M., D. Modilal, R. Anandan, R. Sindhu and M.N. Logeshwari (2015). Screening of *Solanum nigrum* for its phytochemical and antimicrobial activity against respiratory tract pathogens. *International Journal of Pure and Applied Zoology*, 3(3): 210-215.
 26. Senjobi, C.T., Ettu, A.O. and Otujo, C.O. (2017). Antibacterial and antifungal activities of leaf extracts of *phyllanthus amaru* Schum and Thonn. *Journal of Pharmacognosy and Phytotherapy*, 9(1): 6-10.
 27. U.S. Patent Office. (n.d.). Recovery of tigogenin acetate and related compounds (U.S. Patent No. US3303187A). Retrieved January 23, 2026, from <https://patents.google.com/patent/US3303187A/en>
 28. Paul A. A., W. Abimbola O., I. Louis O. (2025) Hepatoprotective Effects and Ameliorative Potential of *Solanum nigrum* Leaf Extract on Biochemical and Histological Alterations in CCl₄-Induced Liver Injury in Rats, *International Journal of Biochemistry Research & Review*, 34(4), 350-361.
 29. Saima Jan1, Sana Iram (2024) Unleashed Treasures of Solanaceae: Mechanistic Insights into Phytochemicals with Therapeutic Potential for Combatting Human Diseases, *Plants*, 13(5), 724;
 30. Lin HM et al. Hepatoprotective effects of *Solanum nigrum* Linn extract against CCl₄-induced oxidative damage in rats. *Chem Biol Interact*;171(3):283-93.
 31. Shailabi TI et al. (2025) Antioxidant and protective effects of methanolic *Solanum nigrum* leaf extract against CCl₄-induced hepatotoxicity and renotoxicity in albino rats. *Open Vet J*. 2025 Apr 30;15(4):1585–1592
 32. Iluz-Freundlich D, Zhang M, Uhanova J, Minuk GY. The relative expression of hepatocellular and cholestatic liver enzymes in adult patients with liver disease. *Ann Hepatol*. 2020 Mar-Apr;19(2):204-208
 33. Vagvala SH, O'Connor SD. Imaging of abnormal liver function tests. *Clin Liver Dis (Hoboken)*. 2018 May;11(5):128-134
 34. Elshater A.E.A., Salman M.M.A., Mohamed S.A. (2013) The hepatameliorating effect of *Solanum nigrum* against CCL₄ induced liver toxicity in Albino rats. *Acad. J. Biol. Sci. C Physiol. Mol. Biol.*;5:59–66.
 35. Krithika R., Verma R.J. (2018) Hypolipidemic and hypoglycemic effects of hydroalcoholic extract of *Solanum nigrum* Linn. in CCl₄-induced hepatotoxicity in mice. *Toxicol. Environ. Health Sci.*;10:268–277.
 36. Liu F.P., Ma X., Li M.M., Li Z., Han Q., Li R., Li C.W., Chang Y.C., Zhao C.W., Lin Y.X. (2016) Hepatoprotective effects of *Solanum nigrum* against ethanol-induced injury in primary hepatocytes and mice with analysis of glutathione S-transferase A1. *J. Chin. Med. Assoc.*;79:65–71.